Table 1.
General information for all studies selected (N = 46)
| Number | Percent | |
|---|---|---|
| Disease stage | ||
| Metastatic / Advanced | 20 | 43.5 |
| Non metastatic / Local | 5 | 10.9 |
| Both | 12 | 26.1 |
| Unclear or not reported | 9 | 19.5 |
| Type of study | ||
| Randomized clinical trials | 10 | 21.7 |
| Prospective cohort study | 23 | 50 |
| Other | 13 | 28.3 |
| International study | ||
| Yes | 9 | 19.6 |
| No | 37 | 80.4 |
| Multicenter study | ||
| Yes | 22 | 47.8 |
| No | 13 | 28.3 |
| Unclear or not reported | 11 | 23.9 |
| Questionnaires | ||
| EORTC QLQ-C30 | 10 | 21.7 |
| EORTC QLQ-C15-PAL | 2 | 4.3 |
| EORTC specific modules | 6 | 13.0 |
| FACT-G | 1 | 2.2 |
| Other FACT questionnaires | 13 | 21.7 |
| Other multidimensional questionnaires | 8 | 17.4 |
| Other specific PRO questionnaires | 13 | 28.2 |